- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1,519)
42 result(s) found for: TAT.
Displaying page 1 of 3.
EudraCT Number: 2007-007200-16 | Sponsor Protocol Number: ISS T-002 | Start Date*: 2008-06-13 | |||||||||||
Sponsor Name:ISTITUTO SUPERIORE DI SANITA' | |||||||||||||
Full Title: A Phase II randomized, open label, immunogenicity and safety trial of the vaccine based on the recombinant biologically active HIV-1 Tat protein in anti-Tat negative HIV-1 infected HAART-treated ad... | |||||||||||||
Medical condition: HIV-1 infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000881-73 | Sponsor Protocol Number: 35RC14_9754_PRADA | Start Date*: 2015-07-27 | |||||||||||
Sponsor Name:CHU de Rennes | |||||||||||||
Full Title: Multicentre, cross-over, PRAgmatic trial in Atopic Dermatitis testing long-term control effectiveness of new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D sup... | |||||||||||||
Medical condition: Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000309-34 | Sponsor Protocol Number: 7654321 | Start Date*: 2016-06-10 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Vorapaxar in the human endotoxemia model | ||
Medical condition: LPS induced acute inflammatory state in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004909-33 | Sponsor Protocol Number: LCTU122 | Start Date*: 2015-09-21 | ||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | ||||||||||||||||||
Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer | ||||||||||||||||||
Medical condition: Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001655-13 | Sponsor Protocol Number: NL2021-8172 | Start Date*: 2021-04-01 |
Sponsor Name:Radboudumc | ||
Full Title: SARS-CoV2 vaccination and activation of the coagulation system | ||
Medical condition: Coronavirus disease 2019 and thromboembolism | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2023-000156-38 | Sponsor Protocol Number: 20230123SE | Start Date*: 2023-05-04 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology | ||||||||||||||||||||||||||||||||||||||
Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes. | ||||||||||||||||||||||||||||||||||||||
Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001019-23 | Sponsor Protocol Number: 04-TH01-01 | Start Date*: 2005-05-11 |
Sponsor Name:BioInvent International AB | ||
Full Title: A double blind, phase I/II, randomized, single and repeat dose, dose escalation study of the antibody BI-201 directed against Tat, given IV, versus Placebo in asymptomatic HIV-1 patients. | ||
Medical condition: HIV-1 (asymptomatic patients) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000631-25 | Sponsor Protocol Number: 2007-000631-25 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:KAROLINSKA INSTITUTET | |||||||||||||
Full Title: THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION | |||||||||||||
Medical condition: ESSENTIAL HYPERTENSION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001674-80 | Sponsor Protocol Number: ARG-E04 | Start Date*: 2005-06-13 | |||||||||||
Sponsor Name:Mitsubishi Pharma Corporation | |||||||||||||
Full Title: A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients u... | |||||||||||||
Medical condition: Stable coronary artery disease (CAD) or unstable angina (troponin negative, i.e. within the normal range for the study site) with low to moderate anatomic risk and a requirement for elective percut... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004911-79 | Sponsor Protocol Number: AR-01 | Start Date*: 2007-10-17 | |||||||||||
Sponsor Name:cliniques Universitaires st luc-ucl | |||||||||||||
Full Title: Pharmacodynamics of Fondaparinux subcutaneous versus continuous intravenous infusion in critically ill patients with or without vasopressors. | |||||||||||||
Medical condition: Thromboprophylaxis to critically ill patients hospitalized in ICU with or without vasopressors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001774-23 | Sponsor Protocol Number: 020518-1 | Start Date*: 2018-07-19 |
Sponsor Name:Tampere university hospital | ||
Full Title: Clinical Drug Trial: Efficacy, safety and pharmacokinetics of tinzaparin during Slow Low Efficient Daily Dialysis in Intensive Care Patients | ||
Medical condition: Patients with clinical indication for pharmacological thromboprophylaxis and slow low efficient daily dialysis (SLEDD). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002093-32 | Sponsor Protocol Number: LUM-002 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:Lument AB | |||||||||||||
Full Title: Randomised, open, non-inferiority within patient-controlled trial evaluating the diagnostic usefulness of Lumentin® 44 when used as contrast agent in CT-enterography as compared to MRI- enterograph... | |||||||||||||
Medical condition: None. Lumentin 44 is a contrast agent. The diagnostic usefulness of CT with Lumentin 44 as contrast agent as compared to MRE will be investigated in this trial. Patients with confirmed small bowel... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020113-85 | Sponsor Protocol Number: CSLCT-BIO-l0-67 | Start Date*: 2011-09-20 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihaemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune To... | |||||||||||||
Medical condition: Male paediatric subjects with Haemophilia A who develped high titre antibodies to human coagulation Factor VIII | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) AT (Completed) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004421-28 | Sponsor Protocol Number: A2171084 | Start Date*: 2006-11-09 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIE... | |||||||||||||
Medical condition: Diabetes Mellitus type II (not insulin independent) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004307-40 | Sponsor Protocol Number: ATN-106 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing sur... | |||||||||||||
Medical condition: Congenital antithrombin deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002741-29 | Sponsor Protocol Number: CMAA868A2202 | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis bioma... | |||||||||||||
Medical condition: atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Suspended by CA) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004189-64 | Sponsor Protocol Number: Hi_Tech_v1 | Start Date*: 2015-08-05 |
Sponsor Name:Erasmus MC | ||
Full Title: Hunting for the off-target properties of ticagrelor on endothelial function and other circulating biomarkers in humans | ||
Medical condition: Acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001779-31 | Sponsor Protocol Number: FONDAPARINUX | Start Date*: 2008-05-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux | |||||||||||||
Medical condition: heart failure patients (III-IV NYHA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004955-38 | Sponsor Protocol Number: NL38327.018.11 | Start Date*: 2011-12-16 | ||||||||||||||||
Sponsor Name:AMC, Amsterdam | ||||||||||||||||||
Full Title: Controlling Glucose during Elective hip Surgery to study the influence on Coagulation | ||||||||||||||||||
Medical condition: patients who will undergo elective hip surgery with a hyperglycemic period perioperatively due to surgery. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005292-10 | Sponsor Protocol Number: ERRADVIH-02 | Start Date*: 2008-12-09 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal | |||||||||||||
Full Title: ESTUDIO PILOTO DEL EFECTO DE UN INHIBIDOR DE LA INTEGRASA SOBRE LA LATENCIA Y EL RESERVORIO DEL VIH-1 EN PACIENTES QUE RECIBEN TRATAMIENTO ANTIRRETROVIRAL DE GRAN ACTIVIDAD | |||||||||||||
Medical condition: Infección por el virus de la inmunodeficiencia humana (VIH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
